Acetylshikonin suppresses diffuse large B-Cell Lymphoma cell growth by targeting the T-lymphokine-activated killer cell-originated protein kinase signalling pathway-Reference-Cited by-同舟云学术

Acetylshikonin suppresses diffuse large B-Cell Lymphoma cell growth by targeting the T-lymphokine-activated killer cell-originated protein kinase signalling pathway

Published:2022-02-01 Issue:2 Volume:13 Page:4428-4440
ISSN:2165-5979
Container-title:Bioengineered
language:en
Short-container-title:Bioengineered

Author:

Cui Jieke¹,Guo Rong¹,Wang Yingjun²,Song Yue²,Song Xuewen³,Li Hongwen²,Song Xiaoqin⁴,Li Jiwei²

Affiliation:

1. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

2. Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

3. Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

4. Depatment of Physical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Funder

the Medical Science and Technology Project of Henan Province

Publisher

Informa UK Limited

Subject

Applied Microbiology and Biotechnology,General Medicine,Bioengineering,Biotechnology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21655979.2022.2034584

Reference34 articles.

1. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway

3. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

4. High total metabolic tumor volume at baseline predicts survival independent of response to therapy

5. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity